Herantis Pharma reports positive topline data for HER-096 in Phase 1b trial for Parkinson’s disease. Results show both 200 mg and 300 mg doses are safe and well tolerated. Blood-brain barrier penetration confirmed. Phase 2 trial planned for 2026. Webcast on October 8th. Full dataset expected by end of 2025.

Clinical trial funded by The Michael J. Fox Foundation and Parkinson’s UK. Study conducted in Turku and Helsinki, Finland. Phase 1b trial demonstrates safety and tolerability of HER-096 in Parkinson’s patients. Plans for Phase 2 trial in early-stage Parkinson’s patients in 2026.

HER-096, a first-in-class drug candidate, aims to stop Parkinson’s disease progression. Combines neuroprotective mechanisms and subcutaneous administration. Phase 1b trial successful. Plans for Phase 2 trial in 2026. Topline data expected by end of 2025.

Read more at GlobeNewswire: Herantis Pharma presents positive topline data for HER-096